Antimicrobial Agents Practice Questions

Q: What is the recommended daily dose of Isoniazid for children?

10-20 mg/kg. The correct answer is **B. 10-20 mg/kg**. ### **Explanation** Isoniazid (INH) is a cornerstone of Antitubercular Therapy (ATT). In pediatric patients, the metabolic rate of drugs is generally higher than in adults. According to the **WHO** and the **National Tuberculosis Elimination Program (NTEP)** guidelines, the recommended daily dose of Isoniazid for children is **10-15 mg/kg** (with a range extending up to **20 mg/kg** in some clinical scenarios). This higher weight-based dosage compared to adults is necessary to achieve therapeutic plasma concentrations, as children are often "rapid acetylators." ### **Analysis of Options** * **Option A (5 mg/kg):** This is the standard daily dose for **adults**, not children. Using this dose in children would lead to sub-therapeutic levels and potential treatment failure. * **Option C (15-25 mg/kg):** This range is typically associated with **Ethambutol** (15-25 mg/kg) or Pyrazinamide (30-35 mg/kg) in certain pediatric protocols. * **Option D (20-40 mg/kg):** This is an excessively high dose for Isoniazid and would significantly increase the risk of hepatotoxicity and neurotoxicity. ### **High-Yield Clinical Pearls for NEET-PG** * **Mechanism of Action:** Inhibits the synthesis of **mycolic acids** by targeting the *InhA* enzyme. * **Metabolism:** Metabolized via **Acetylation** (Phase II reaction). Genetic polymorphism leads to "Fast" and "Slow" acetylators. * **Side Effects:** Peripheral neuropathy (due to **Vitamin B6/Pyridoxine deficiency**) and Hepatotoxicity (most common). * **Prophylaxis:** Isoniazid is the drug of choice for Chemoprophylaxis in household contacts of TB patients (dose: 10 mg/kg for children). * **Supplementation:** Always co-prescribe **Pyridoxine (10-25 mg/day)** in children to prevent peripheral neuropathy.

Q: Bacitracin is a:

Topical antibiotic. **Explanation:** **Bacitracin** is a polypeptide antibiotic primarily used as a **topical agent**. Its mechanism of action involves inhibiting cell wall synthesis by interfering with the dephosphorylation of the C55-isoprenyl pyrophosphate (bactoprenol), which transports peptidoglycan subunits across the cell membrane. **Why Option B is Correct:** Bacitracin is highly effective against Gram-positive bacteria (like *Staphylococci* and *Streptococci*). However, it is **highly nephrotoxic** when administered systemically. Therefore, its clinical use is strictly restricted to topical applications (ointments/creams) for skin infections, wounds, and ophthalmic preparations to ensure local efficacy without systemic toxicity. **Why Other Options are Incorrect:** * **Option A (Oral):** Bacitracin is not absorbed from the gastrointestinal tract. While some non-absorbable antibiotics are used for bowel preparation (e.g., Neomycin), Bacitracin is not used this way. * **Option C (Parenteral):** Systemic (parenteral) administration is obsolete due to severe **nephrotoxicity** (tubular and glomerular damage). It was historically used for infant pneumonia but has been replaced by safer alternatives. **High-Yield Clinical Pearls for NEET-PG:** * **Mechanism:** Inhibits the lipid carrier **bactoprenol** (unlike Penicillins, which inhibit transpeptidation). * **Spectrum:** Primarily Gram-positive organisms. * **Triple Antibiotic Ointment:** Bacitracin is often combined with **Neomycin** and **Polymyxin B** (Neosporin) to provide broad-spectrum coverage. * **Zinc Bacitracin:** The addition of zinc stabilizes the compound and enhances its antibacterial activity.

Q: Which of the following drugs is NOT effective against anaerobes?

Gentamicin. **Explanation:** The correct answer is **Gentamicin**. **1. Why Gentamicin is the correct answer:** Gentamicin is an **Aminoglycoside**. The transport of aminoglycosides across the bacterial cell membrane is an **oxygen-dependent active process**. In anaerobic environments, there is a lack of oxygen to drive this transport mechanism; therefore, the drug cannot enter the bacterial cell to reach its target (the 30S ribosome). Consequently, all aminoglycosides exhibit an **innate resistance** to obligate anaerobes. **2. Analysis of Incorrect Options:** * **Penicillin:** While many Gram-negative anaerobes produce beta-lactamases, Penicillin G remains highly effective against most **Gram-positive anaerobes** (e.g., *Peptostreptococcus*) and non-beta-lactamase-producing Gram-negative anaerobes (e.g., *Fusobacterium*). * **Chloramphenicol:** This is a broad-spectrum antibiotic with excellent tissue penetration and potent activity against most anaerobic bacteria, including *Bacteroides fragilis*. It is often reserved for serious anaerobic infections when other drugs are contraindicated. * **Clindamycin:** This is a classic anti-anaerobic agent. It is particularly effective against anaerobes "above the diaphragm" and is a first-line choice for lung abscesses and dental infections. **3. NEET-PG High-Yield Pearls:** * **Mnemonic for Anaerobic Coverage:** "Can't Breathe Air" (**C**lindamycin, **B**eta-lactams/Metronidazole, **A**minoglycosides = **NO**). * **Aminoglycoside Synergy:** Because they lack anaerobic activity, aminoglycosides are frequently combined with Beta-lactams (which disrupt cell wall synthesis) to facilitate drug entry and broaden the spectrum. * **Metronidazole** is the gold standard for anaerobes "below the diaphragm" (e.g., *B. fragilis*).

Q: Which drug is frequently associated with the development of noninfectious chronic meningitis?

Ibuprofen. **Explanation:** The correct answer is **Ibuprofen**. This question tests the concept of **Drug-Induced Aseptic Meningitis (DIAM)**, a rare but clinically significant hypersensitivity reaction. **1. Why Ibuprofen is Correct:** Ibuprofen is the most common pharmacological trigger for DIAM. The underlying mechanism is believed to be a **Type III or Type IV hypersensitivity reaction** rather than direct toxicity. It typically presents with classic meningeal signs (fever, headache, nuchal rigidity) and CSF pleocytosis (predominantly neutrophils), but with negative cultures. A high-yield association for NEET-PG is that DIAM occurs more frequently in patients with underlying autoimmune conditions, particularly **Systemic Lupus Erythematosus (SLE)**. **2. Why the Other Options are Incorrect:** * **Cefepime:** While cephalosporins can cause neurotoxicity (especially in renal failure), it typically manifests as **encephalopathy, myoclonus, or seizures**, not chronic meningitis. * **Acyclovir:** High doses or rapid infusion can lead to **crystalline nephropathy** or neurotoxicity (confusion, tremors), but it is not a recognized cause of noninfectious meningitis. * **Phenobarbital:** This barbiturate is associated with sedation, respiratory depression, and Stevens-Johnson Syndrome, but not aseptic meningitis. **3. Clinical Pearls for NEET-PG:** * **Common DIAM Triggers:** NSAIDs (Ibuprofen, Naproxen), IVIG, OKT3 (Muromonab-CD3), and certain antibiotics (Trimethoprim-Sulfamethoxazole). * **CSF Findings:** Elevated protein, normal glucose, and pleocytosis (mimics bacterial meningitis, but cultures are sterile). * **Management:** Symptoms usually resolve within 24–48 hours of discontinuing the offending drug. * **Key Association:** Always suspect Ibuprofen-induced meningitis in an SLE patient presenting with meningeal signs and negative cultures.

Q: Which of the following statements is false about Acyclovir?

It is effective against influenza. ### Explanation **1. Why Option B is the correct (False) statement:** Acyclovir is a narrow-spectrum antiviral agent specifically targeting the **Herpesvirus family** (HSV-1, HSV-2, and VZV) [1]. It is **ineffective against Influenza**, which is an RNA virus [2]. Influenza is treated with neuraminidase inhibitors (e.g., Oseltamivir) or M2 ion channel blockers (e.g., Amantadine). **2. Analysis of other options:** * **Option A (Mechanism):** Acyclovir is a guanosine analogue [2]. It undergoes initial phosphorylation by viral **thymidine kinase** to acyclovir monophosphate, then to triphosphate by host cell kinases [2]. This active form acts as a competitive inhibitor of **viral DNA polymerase** and causes **DNA chain termination**, thereby inhibiting replication [1]. * **Option C (Toxicity):** It has high selectivity and **low host toxicity** because the initial activation step requires a viral enzyme (thymidine kinase), which is absent in non-infected human cells [2]. * **Option D (Pharmacokinetics):** Acyclovir is primarily excreted unchanged via glomerular filtration and tubular secretion [1]. In patients with **renal impairment**, the drug can accumulate, leading to neurotoxicity or obstructive uropathy (crystalline nephropathy); hence, dose adjustment is mandatory [1]. **3. NEET-PG High-Yield Pearls:** * **Drug of Choice (DOC):** Herpes Simplex Encephalitis, Genital Herpes, and Chickenpox/Zoster in immunocompromised patients. * **Resistance:** Most commonly due to the absence or mutation of the viral **thymidine kinase** enzyme [3]. * **Valacyclovir:** A prodrug of acyclovir with much higher oral bioavailability (the "Val" prefix often denotes improved bioavailability in antivirals) [1]. * **Side Effect:** Intravenous administration can cause **reversible crystalline nephropathy**; ensure adequate hydration.

Q: Erythromycin acts by binding to the 50S ribosomal subunit and interferes with which step of protein synthesis in bacteria?

Translocation. **Explanation:** **Mechanism of Action:** Erythromycin belongs to the **Macrolide** class of antibiotics. It exerts its bacteriostatic effect by reversibly binding to the **23S rRNA of the 50S ribosomal subunit**. This binding specifically inhibits the enzyme **peptidyl transferase** and prevents the **translocation** step. During translocation, the growing peptide chain moves from the A-site (aminoacyl) to the P-site (peptidyl) on the ribosome. By blocking this movement, erythromycin halts protein synthesis. **Analysis of Options:** * **Translocation (Correct):** This is the specific movement of the ribosome along the mRNA template. Macrolides (Erythromycin, Azithromycin, Clarithromycin) are classic inhibitors of this step. * **Transcription (Incorrect):** This is the process of DNA being copied into RNA, catalyzed by RNA polymerase. Drugs like **Rifampicin** inhibit this step. * **Translation (Incorrect):** While translocation is a *part* of translation, "translation" is too broad a term. The question asks for the specific step within the protein synthesis cycle. * **Transduction (Incorrect):** This is a process of horizontal gene transfer in bacteria mediated by **bacteriophages** (viruses), not a step in protein synthesis. **Clinical Pearls for NEET-PG:** * **Resistance Mechanism:** The most common mechanism of resistance to Macrolides is **methylation of the 23S rRNA** (via *erm* genes), which prevents drug binding. * **Prokinetic Effect:** Erythromycin acts as a **Motilin receptor agonist**, making it useful in treating diabetic gastroparesis. * **Drug Interactions:** Erythromycin is a potent **CYP3A4 inhibitor**, leading to increased levels of drugs like Theophylline, Warfarin, and Statins. * **Adverse Effect:** It is a notorious cause of **cholestatic jaundice** (especially the estolate salt) and QT interval prolongation.

Q: Which drug is the drug of choice for Listeria monocytogenes infection?

Ampicillin. **Explanation:** **Listeria monocytogenes** is a Gram-positive, facultative intracellular bacillus often associated with foodborne illness, neonatal sepsis, and meningitis in immunocompromised individuals. **1. Why Ampicillin is the Correct Answer:** Ampicillin is considered the **drug of choice (DOC)** for *Listeria* because it exhibits excellent bactericidal activity against this specific pathogen. Unlike many other bacteria, *Listeria* is naturally susceptible to aminopenicillins. In clinical practice, especially for meningitis, Ampicillin is often combined with **Gentamicin** to achieve a synergistic effect, ensuring rapid clearance of the bacteria from the intracellular compartment. **2. Analysis of Incorrect Options:** * **Amoxycillin (A):** While pharmacologically similar to Ampicillin, it is primarily used for oral therapy. Ampicillin is preferred in the acute, systemic, or meningeal presentations typical of *Listeria* due to its established intravenous efficacy [2]. * **Amikacin (C):** This is an aminoglycoside. While aminoglycosides are used as adjuncts for synergy, they cannot be used as monotherapy because they have poor intracellular penetration and limited activity against Gram-positive bacilli when used alone. * **Ceftriaxone (D):** This is a high-yield "trap." **Listeria is inherently resistant to all Cephalosporins.** This is a critical clinical fact [2]: when treating empirical bacterial meningitis, Ampicillin must be added to the Ceftriaxone + Vancomycin regimen if *Listeria* is suspected (e.g., in neonates or the elderly) [1]. **3. High-Yield Clinical Pearls for NEET-PG:** * **The "Listeria Gap":** Cephalosporins do not cover *Listeria* [1]. * **DOC in Penicillin Allergy:** Trimethoprim-Sulfamethoxazole (TMP-SMX). * **At-risk groups:** Neonates (granulomatosis infantiseptica), pregnant women, and the elderly. * **Synergy:** Ampicillin + Gentamicin is the gold standard for serious infections.

Q: Which of the following drugs is not used in the treatment of leprosy?

Kanamycin. **Explanation:** The treatment of Leprosy (Hansen’s Disease) is based on **Multi-Drug Therapy (MDT)** to prevent the emergence of resistance in *Mycobacterium leprae*. **Why Kanamycin is the correct answer:** Kanamycin is an aminoglycoside primarily used in the treatment of **Multi-Drug Resistant Tuberculosis (MDR-TB)** as a second-line injectable drug. It is not part of the standard WHO regimens for Leprosy. While some other aminoglycosides (like Amikacin) have shown experimental activity against *M. leprae*, Kanamycin is not clinically utilized for this indication. **Analysis of other options:** * **Rifampicin (Option A):** The most bactericidal drug against *M. leprae*. It is the backbone of MDT for both Paucibacillary (PB) and Multibacillary (MB) leprosy, usually administered as a supervised monthly dose (600 mg). * **Dapsone (Option B):** A bacteriostatic sulfonamide that inhibits folate synthesis. It has been the standard treatment for leprosy for decades and is a core component of both PB and MB regimens. * **Clofazimine (Option C):** A dye with both weak bactericidal and significant anti-inflammatory properties. It is essential in treating MB leprosy and is highly effective in managing **Type 2 Lepra Reactions (ENL)**. **High-Yield Clinical Pearls for NEET-PG:** * **WHO MDT Regimen (MB Leprosy):** Rifampicin (600mg monthly), Dapsone (100mg daily), and Clofazimine (300mg monthly + 50mg daily) for 12 months. * **Alternative Drugs:** If primary drugs cannot be used, **Minocycline, Ofloxacin, and Clarithromycin** are considered effective alternatives. * **Side Effects:** Watch for **Dapsone-induced hemolysis** (especially in G6PD deficiency) and **Clofazimine-induced skin discoloration** (reddish-black).

Q: Which of the following is NOT a hepatotoxic antitubercular drug?

Ethambutol. **Explanation:** The primary adverse effect profile of first-line Antitubercular Drugs (ATT) is a high-yield topic for NEET-PG. Hepatotoxicity is the most common serious side effect of the standard RIPE regimen, but it is not caused by all four drugs. **1. Why Ethambutol is the correct answer:** Ethambutol is unique among first-line ATT drugs because it is **not hepatotoxic**. It is primarily excreted by the kidneys. Its dose-limiting toxicity is **Optic Neuritis**, characterized by decreased visual acuity and loss of red-green color discrimination. Therefore, it is the drug of choice when a patient develops drug-induced hepatitis from other ATT agents. **2. Why the other options are incorrect:** * **Pyrazinamide (D):** This is the **most hepatotoxic** drug among the first-line agents. It can cause both dose-dependent hepatotoxicity and hyperuricemia. * **Isoniazid (B):** It is significantly hepatotoxic. The risk increases with age and in "slow acetylators" due to the accumulation of the metabolite monoacetylhydrazine. * **Rifampicin (C):** It causes hepatotoxicity, often presenting as asymptomatic jaundice (cholestatic pattern). It is also a potent inducer of Cytochrome P450 enzymes. **Clinical Pearls for NEET-PG:** * **Hepatotoxicity Ranking:** Pyrazinamide > Isoniazid > Rifampicin. * **Visual Monitoring:** Patients on Ethambutol must undergo baseline and monthly visual acuity and color vision testing (Snellen’s and Ishihara charts). * **Safe in Liver Disease:** If a patient has pre-existing liver disease, the preferred regimen often includes **Ethambutol and Streptomycin**, as both are non-hepatotoxic. * **Management:** If AST/ALT levels rise >3 times the upper limit of normal with symptoms (or >5 times without symptoms), hepatotoxic drugs should be stopped immediately.

Question 1

What is the recommended daily dose of Isoniazid for children?

Accepted Answer

10-20 mg/kg

Answer

5 mg/kg

Answer

15-25 mg/kg

Answer

20-40 mg/kg

Question 2

Bacitracin is a:

Accepted Answer

Topical antibiotic

Answer

Oral antibiotic

Answer

Parenteral antibiotic

Answer

All of the above

Question 3

Which of the following drugs is NOT effective against anaerobes?

Accepted Answer

Gentamicin

Answer

Penicillin

Answer

Chloramphenicol

Answer

Clindamycin

Question 4

Which drug is frequently associated with the development of noninfectious chronic meningitis?

Accepted Answer

Ibuprofen

Answer

Cefipime

Answer

Acyclovir

Answer

Phenobarbital

Question 5

Which of the following statements is false about Acyclovir?

Accepted Answer

It is effective against influenza

Answer

It inhibits DNA synthesis and viral replication

Answer

It has low toxicity for host cells

Answer

Renal impairment necessitates dose reduction

Question 6

Erythromycin acts by binding to the 50S ribosomal subunit and interferes with which step of protein synthesis in bacteria?

Accepted Answer

Translocation

Answer

Transcription

Answer

Translation

Answer

Transduction

Question 7

Which drug is the drug of choice for Listeria monocytogenes infection?

Accepted Answer

Ampicillin

Answer

Amoxycillin

Answer

Amikacin

Answer

Ceftriaxone

Question 8

Which of the following statements about the clinical uses of the aminoglycosides is FALSE?

Accepted Answer

The spectrum of antimicrobial activity of aminoglycosides includes Bacteroides fragilis.

Answer

Owing to their polar nature, aminoglycosides are not absorbed following oral administration.

Answer

Aminoglycosides are often used in combination with cephalosporins in the empirical treatment of life-threatening bacterial infections.

Answer

Gentamicin is used with ampicillin for synergistic effects in the treatment of enterococcal endocarditis.

Question 9

Which of the following drugs is not used in the treatment of leprosy?

Accepted Answer

Kanamycin

Answer

Rifampicin

Answer

Dapsone

Answer

Clofazimine

Question 10

Which of the following is NOT a hepatotoxic antitubercular drug?

Accepted Answer

Ethambutol

Answer

Isoniazid

Answer

Rifampicin

Answer

Pyrazinamide

Antimicrobial Agents — MCQs

Antimicrobial Agents — MCQs

On this page

Practice by Chapter

Want unlimited practice?